by Ethan Perlstein | Feb 13, 2018 | NGLY1 |
On the first day of the new year, we submitted a new NGLY1 model preprint titled “Defects in the neuroendocrine axis cause global developmental delay in a Drosophila model of NGLY1 Deficiency.” Follow on Twitter. Here I will explain in plain English what the NGLY1...
by Ethan Perlstein | Jan 19, 2018 | NGLY1 |
Earlier this week I was alerted on Twitter (where else?) to a new NGLY1 paper from Dr. Clement Chow’s lab at the University of Utah titled: “Transcriptome and functional analysis in a Drosophila model of NGLY1 deficiency provides insight into therapeutic approaches,”...
by Ethan Perlstein | Dec 6, 2017 | Perlara science |
This is the fourth post in an open science blog series about PERL101 (P101), a small molecule with big hopes. Demystifying drug discovery The default setting of biotech startups and pharma giants alike is stealth mode. At Perlara the default is set to open. As the...
by Ethan Perlstein | Nov 4, 2017 | Start-ups, Uncategorized |
This week we announced a $7.4M equity financing. Endpoints News and STAT News covered the announcement and the Twitter angle. Here’s the backstory from the CEO’s vantage point. From the outside, this round appears to be our Series A. But it’s technically our...
by Ethan Perlstein | Sep 21, 2017 | Niemann-Pick Type A |
By Taryn Sumabat This summer at Perlara, we ramped up our efforts to develop a Drosophila model of Niemann-Pick Type A (NPA). NPA is a rare lysosomal storage disease caused by mutations in the gene Smpd1, which encodes an enzyme called acid sphingomyelinase (ASM)....
